Nabel's Work Sheds Light on Genetic Factors of Atherosclerosis
Dr. Nabel is a leading scientist and recognized expert in the development of novel genetic and cellular therapies for cardiovascular disease, Dr. Schwartz said in announcing the award.
Throughout her career, Dr. Nabel has championed the concept of "bench to bedside," by translating research discoveries for the clinical benefit of patients. Her current research interests focus on the molecular genetics of vascular diseases, including investigation of how cell cycle proteins regulate the growth of smooth muscle cells (a fundamental process in the development of atherosclerosis).
As director of the NHLBI, Dr. Nabel oversees an extensive national research portfolio with an annual budget of approximately $3 billion, for the prevention, diagnosis, and treatment of heart, lung and blood diseases. Among her leadership efforts, Dr. Nabel has launched new scientific programs in the genomics, stem and progenitor cell biology, translational research, global health and support for young investigators.
Playing an active role in the dissemination of seminal research findings, Dr. Nabel also has more than 15 years of experience as an editor for medical journals. Currently she is an editorial board member of the New England Journal of Medicine and Science Translational Medicine, as well as editor of Trends in Cardiovascular Medicine and ACP Medicine.
Dr. Nabel has received numerous awards, including two Distinguished Achievement Awards from the American Heart Association; the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology; and the Basic Research Prize from the American College of Physicians. In addition to holding several committee memberships at the NIH, she is a member of the Association of Am
|Contact: Alex Lyda|
Columbia University Medical Center